Methotrexate Induces Immune Tolerance for Protein Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein therapeutics often induce unwanted immune responses, such as anti-drug antibodies (ADAs), which can compromise patient safety and efficacy, and existing methods to mitigate these responses are inadequate.
Innovation Solution
Administering a single cycle of methotrexate to induce immune tolerance, inhibit ADAs, and enhance the efficacy of protein therapeutics by increasing regulatory T and B cells, thereby reducing secondary autoimmunity and improving pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein therapeutics are administered to treat patients, then therapeutic efficacy is improved, but anti-drug antibody (ADA) responses are induced which compromise patient safety and drug efficacy
Solution Approach 1:
Methotrexate is administered prior to or concurrently with the protein therapeutic to preemptively suppress the immune system's ability to generate anti-drug antibodies. This preliminary immunosuppressive action prevents the harmful ADA response before it can develop, while allowing the therapeutic protein to exert its beneficial effects.
Solution Approach 2:
Methotrexate serves as an intermediary substance that mediates between the protein therapeutic and the patient's immune system. It interferes with immune cell function and reduces immune responsiveness, thereby preventing the immune system from mounting an adverse response against the therapeutic while preserving the therapeutic's efficacy.
2Object-affected harmful factors
If existing immunosuppressive methods are used to mitigate ADA responses, then immune responses are reduced, but treatment complexity and side effects increase
Solution Approach 1:
The invention changes the dosing parameters of methotrexate from conventional high-dose, frequent administration to a reduced dose administered once monthly. This parameter change maintains sufficient immunosuppressive effect to prevent ADA formation while minimizing treatment complexity and reducing the burden of frequent dosing.
Solution Approach 2:
Instead of using full-dose conventional immunosuppressive regimens, the invention employs a partial dose of methotrexate (lower than typical immunosuppressive doses) that is sufficient to prevent ADA formation without causing excessive immunosuppression or requiring complex combination therapies.
Data Source
AI summary
The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.